Literature DB >> 27463694

Folate-PEG-decorated docetaxel lipid nanoemulsion for improved antitumor activity.

Syed Muzammil Afzal1, Mohammad Zubair Shareef2, Tummuri Dinesh3, Veerabrahma Kishan1.   

Abstract

AIM: To develop a folate-based docetaxel lipid nanoemulsion (FLNE) for tumor-targeted treatment. MATERIALS &
METHODS: The docetaxel LNEs were prepared and characterized. In vitro cytotoxic and cell uptake studies were performed. The tissue distribution and targeting of drug were studied by fluorescence imaging and tumor regression in mice.
RESULTS: The IC50 values of FLNE on cancer cells were significant. The cell uptake studies showed an increase in fluorescence with time. Imaging studies found that FLNE was superior in tumor targeting by 4.81- and 2.08-fold over controls. The tumor regression proved the superiority of FLNEs.
CONCLUSION: The folate strategy was superior over PEGylation, albumin and transferrin strategies. The study demonstrated great potential of FLNE as a prospective targeted delivery system.

Entities:  

Keywords:  fluorescent LNE cell uptake; fluorescent tissue distribution; folate-containing emulsion; improved targeting; noninvasive imaging study; targeted docetaxel lipid emulsion

Mesh:

Substances:

Year:  2016        PMID: 27463694     DOI: 10.2217/nnm-2016-0120

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  2 in total

1.  iRGD-functionalized PEGylated nanoparticles for enhanced colon tumor accumulation and targeted drug delivery.

Authors:  Lijun Ma; Qiubing Chen; Panpan Ma; Moon Kwon Han; Zhigang Xu; Yuejun Kang; Bo Xiao; Didier Merlin
Journal:  Nanomedicine (Lond)       Date:  2017-07-26       Impact factor: 5.307

2.  Excipient selection and aerodynamic characterization of nebulized lipid-based nanoemulsion loaded with docetaxel for lung cancer treatment.

Authors:  Azren Aida Asmawi; Norazlinaliza Salim; Cheng Loong Ngan; Haslina Ahmad; Emilia Abdulmalek; Mas Jaffri Masarudin; Mohd Basyaruddin Abdul Rahman
Journal:  Drug Deliv Transl Res       Date:  2019-04       Impact factor: 4.617

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.